Enhancement of transient gene expression and culture viability using Chinese hamster ovary cells overexpressing Bcl‐xL
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Transient gene expression (TGE) provides a method for quickly delivering protein for research using mammalian cells. While high levels of recombinant proteins have been produced in TGE experiments in HEK 293 cells, TGE efforts in the commercially prominent CHO cell line still suffer from inadequate protein yields. Here, we describe a cell‐engineering strategy to improve transient production of proteins using CHO cells. CHO‐DG44 cells were engineered to overexpress the anti‐apoptotic protein Bcl‐x L and transiently transfected using polyethylenimine (PEI) in serum‐free media. Pools and cell lines stably expressing Bcl‐x L showed enhanced viable cell density and increased production of a glycosylated, therapeutic fusion protein in shake flask TGE studies. The improved cell lines showed fusion protein production levels ranging from 12.6 to 27.0 mg/L in the supernatant compared to the control cultures which produced 6.3–7.3 mg/L, representing a 70–270% increase in yield after 14 days of fed‐batch culture. All Bcl‐x L‐expressing cell lines also exhibited an increase in specific productivity during the first 8 days of culture. In addition to increased production, Bcl‐x L cell lines maintained viabilities above 90% and less apoptosis compared to the DG44 host which had viabilities below 60% after 14 days. Product quality was comparable between a Bcl‐x L‐engineered cell line and the CHO host. The work presented here provides the foundation for using anti‐apoptosis engineered CHO cell lines for increased production of therapeutic proteins in TGE applications. Biotechnol. Bioeng. 2008;101: 567–578. © 2008 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Vander Heiden, M. G., Li, X. X., Gottleib, E., Hill, R. B., Thompson, C. B., & Colombini, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101590200 · Cited by 372 · cited 1×
“…binding pro-apoptotic proteins (Cheng et al., 576 Biotechnology and Bioengineering, Vol. 101, No. 3, October 15, 2008 2001), modulation of mitochondrial pores (Vander Heiden et al., 2001) and ER calcium channels (White et al., 2005), and alternation of mitochondria morphology (Zheng et al., 2007).”
BackgroundFerrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305 · cited 2×
“The cell-DNA solution was transferred to a Biorad 0.4 cm gap electroporation cuvette and subjected to a single pulse as described previously (Ferrara et al., 2006).”
MethodInfluentialLarge-Scale transfection of mammalian cells for the fast production of recombinant protein
Pham, P. L., Kamen, A., & Durocher, Y. (2006) · Molecular Biotechnology · doi:10.1385/mb:34:2:225 · Cited by 236 · cited 1×
“…represents an attractive alternative to stable mammalian production cell lines for these applications (Baldi et al., 2007; Carpentier et al., 2007; Derouazi et al., 2004; Geisse and Henke 2005; Pham et al., 2005, 2006; Schlaeger and Christensen 1999; Sun et al., 2007; Wurm and Bernard 1999).”
BackgroundTigges, M., & Fussenegger, M. (2006) · Metabolic Engineering · doi:10.1016/j.ymben.2006.01.006 · Cited by 178 · cited 2×
“…complements innovations in expression technology, including vector design (Ng et al., 2007), host cell development (Prentice et al., 2007a), secretion engineering (Tigges and Fussenegger, 2006), small molecule treatments (Hunt et al., 2002), and media development (Luo and Chen, 2007) among others.”
BackgroundEpisomal vectors for gene expression in mammalian cells
Van Craenenbroeck, K., Vanhoenacker, P., & Haegeman, G. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01645.x · Cited by 147 · cited 1×
“Advances in expression vector technology (Van Craenenbroeck et al., 2000) coupled with cell lines expressing the Epstein Barr virus (EBV) nuclear antigen 1 (EBNA1) or SV40 large-T antigen for episomal replication of the transfected vectors have allowed for significant gains in recombinant protein…”
BackgroundMeents, H., Enenkel, B., Eppenberger, H. M., Werner, R. G., & Fussenegger, M. (2002) · Biotechnology and Bioengineering · doi:10.1002/bit.10449 · Cited by 92
Rosser, M. P., Xia, W., Hartsell, S., McCaman, M., Zhu, Y., Wang, S., Harvey, S., Bringmann, P., & Cobb, R. R. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2004.07.015 · Cited by 68
Cited by
Mammalian cell protein expression for biopharmaceutical production
Zhu, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.022 · Cited by 491
Synthetic Biology and Metabolic Engineering
Stephanopoulos, G. (2012) · ACS Synthetic Biology · doi:10.1021/sb300094q · Cited by 274
Recent advances in mammalian protein production
Bandaranayake, A. D., & Almo, S. C. (2014) · FEBS Letters · doi:10.1016/j.febslet.2013.11.035 · Cited by 222
“bers [50–52] and Bcl-x(L) [53,54], which leads to higher viability and improved yields.”
BackgroundDaramola, O., Stevenson, J., Dean, G., Hatton, D., Pettman, G., Holmes, W., & Field, R. (2014) · Biotechnology Progress · doi:10.1002/btpr.1809 · Cited by 134
Dreesen, I. A. J., & Fussenegger, M. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.22990 · Cited by 110
Metadata
- Authors
- Majors, B. S., Betenbaugh, M. J., Pederson, N. E., & Chiang, G. G.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2008-08-26
- Volume
- 101
- Issue
- 3
- Pages
- 567-578
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2103839146
- Cited by
- 69
- References
- 8
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.